La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Pfizer Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Meenakshi Nevatia

Amministratore delegato

₹71.8m

Compenso totale

Percentuale dello stipendio del CEO	67.9%
Mandato del CEO	1.3yrs
Proprietà del CEO	n/a
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	5.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Subdued Growth No Barrier To Pfizer Limited (NSE:PFIZER) With Shares Advancing 25%

Aug 07

This Is The Reason Why We Think Pfizer Limited's (NSE:PFIZER) CEO Deserves A Bump Up To Their Compensation

Aug 12

Are Institutions Heavily Invested In Pfizer Limited's (NSE:PFIZER) Shares?

Mar 10

Why Dividend Hunters Love Pfizer Limited (NSE:PFIZER)

Feb 17

Are Pfizer's (NSE:PFIZER) Statutory Earnings A Good Guide To Its Underlying Profitability?

Feb 02

Need To Know: Pfizer Limited (NSE:PFIZER) Insiders Have Been Buying Shares

Jan 18

Is Pfizer Limited's (NSE:PFIZER) Stock's Recent Performance A Reflection Of Its Financial Health?

Jan 03

What Can We Learn About Pfizer's (NSE:PFIZER) CEO Compensation?

Dec 18

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Meenakshi Nevatia rispetto agli utili di Pfizer?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	₹6b
Mar 31 2024	₹72m	₹49m	₹6b

Compensazione vs Mercato: La retribuzione totale di Meenakshi ($USD 856.16K ) è superiore alla media delle aziende di dimensioni simili nel mercato Indian ($USD 591.43K ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Meenakshi con le performance aziendali.

AMMINISTRATORE DELEGATO

Meenakshi Nevatia (53 yo)

1.3yrs

Mandato

₹71,801,316

Compensazione

Mrs. Meenakshi Nevatia serves as Non-Executive Independent Director at TeamLease Services Ltd. since July 28, 2021. Mrs. Nevatia is the Managing Director of Stryker India since October 2018.She has focuse...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Meenakshi Nevatia	MD & CEO	1.3yrs	₹71.80m	Nessun dato
Amit Agarwal	Executive Director of Finance	less than a year	₹19.34m	Nessun dato
Prajeet Nair	Director of Corporate Services	16.9yrs	₹11.10m	Nessun dato
Pazhania Rengan	Whole-Time Director & Executive Director of Plant Operations	less than a year	₹9.45m	Nessun dato
Anil Pattanshetty	Senior Director of Business Operations	no data	Nessun dato	Nessun dato
Sharad Goswami	Senior Director of Policy & Public Affairs	no data	Nessun dato	Nessun dato
Shilpi Singh	Director of People Experience	no data	Nessun dato	Nessun dato
Chaitanya Nadkarni	India Digital Client Partner Lead	less than a year	Nessun dato	Nessun dato

0.9yrs

Durata media

47yo

Età media

Gestione esperta: Il team dirigenziale di PFIZER non è considerato esperto (durata media 0.9 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Meenakshi Nevatia	MD & CEO	1.3yrs	₹71.80m	Nessun dato
Amit Agarwal	Executive Director of Finance	less than a year	₹19.34m	Nessun dato
Pazhania Rengan	Whole-Time Director & Executive Director of Plant Operations	less than a year	₹9.45m	Nessun dato
Meena Ganesh	Independent Woman Director	5.4yrs	₹2.21m	Nessun dato
Sunil Lalbhai	Non Executive Independent Director	9.5yrs	₹2.37m	0.0054% ₹ 14.7m
Pradip Shah	Non-Executive Independent Chairman of the Board	24.7yrs	₹2.52m	Nessun dato
Uday Khanna	Non Executive Independent Director	12.3yrs	₹2.43m	Nessun dato

5.4yrs

Durata media

61yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PFIZER sono considerati esperti (durata media dell'incarico 5.4 anni).

Pfizer Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Pfizer Limited, Annual General Meeting, Aug 28, 2024

Pfizer Limited, Annual General Meeting, Aug 28, 2024

Pfizer Limited Appoints Amit Agarwal as Chief Financial Officer

Pfizer Limited Informs Satyen Amin, Lead - Market Access Tenders His Resignation from Employment, with Effect from March 31, 2024

Pfizer Limited Appoints Ms. Aditi Mehta as Category Lead, Vaccines Effective December 1, 2023

Pfizer Limited Announces Resignation of Mr. Milind Patil as Director with Effect from Close of Business on November 13, 2023

Recent updates

Dividend of ₹35.00 announced

Pfizer Limited, Annual General Meeting, Aug 28, 2024

Pfizer Limited, Annual General Meeting, Aug 28, 2024

Subdued Growth No Barrier To Pfizer Limited (NSE:PFIZER) With Shares Advancing 25%

Price target increased by 11% to ₹5,477

First quarter 2025 earnings released: EPS: ₹32.94 (vs ₹20.44 in 1Q 2024)

Pfizer Limited to Report Q1, 2025 Results on Jul 29, 2024

Weak Statutory Earnings May Not Tell The Whole Story For Pfizer (NSE:PFIZER)

Full year 2024 earnings released: EPS: ₹121 (vs ₹136 in FY 2023)

Pfizer Limited Recommends Dividend for the Financial Year Ended March 31, 2024, Payable on or Before September 6, 2024

Pfizer Limited to Report Q4, 2024 Results on May 17, 2024

Pfizer Limited Appoints Amit Agarwal as Chief Financial Officer

China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Pfizer (NSE:PFIZER) Has A Pretty Healthy Balance Sheet

Third quarter 2024 earnings released: EPS: ₹28.42 (vs ₹32.93 in 3Q 2023)

Pfizer Limited Informs Satyen Amin, Lead - Market Access Tenders His Resignation from Employment, with Effect from March 31, 2024

Pfizer Limited to Report Q3, 2024 Results on Feb 09, 2024

Pfizer Limited's (NSE:PFIZER) Business Is Yet to Catch Up With Its Share Price

Pfizer Limited Appoints Ms. Aditi Mehta as Category Lead, Vaccines Effective December 1, 2023

Pfizer Limited Announces Resignation of Mr. Milind Patil as Director with Effect from Close of Business on November 13, 2023

Pfizer Limited Announces Resignation of Samir Kazi as Director from the Board of Directors

Second quarter 2024 earnings released: EPS: ₹32.56 (vs ₹67.99 in 2Q 2023)

Pfizer Limited to Report Q2, 2024 Results on Oct 28, 2023

Pfizer Limited Appoints Chaitanya Nadkarni as India Digital Client Partner Lead

Pfizer Limited Approves A Final Dividend for the Financial Year Ended March 31, 2023

New major risk - Revenue and earnings growth

Pfizer Limited Announces Change in Management, Effective September 1, 2023

Pfizer Limited to Report Q1, 2024 Results on Aug 11, 2023

Upcoming dividend of ₹40.00 per share at 0.9% yield

Full year 2023 earnings released: EPS: ₹136 (vs ₹134 in FY 2022)

Pfizer Limited, Annual General Meeting, Aug 18, 2023

Pfizer Limited Proposes Final Dividend for the Financial Year Ended March 31, 2023

Pfizer Limited Initiates Voluntary Recall Of Magnex 1gm, 2gm, Magnex Forte 1.5gm, 3gm, Zosyn 4.5gm and Magnamycin 250mg, 1gm, 2gm Injections

Price target decreased by 7.9% to ₹4,595

Pfizer Limited Recommends A Final Dividend for the Financial Year Ended March 31, 2023, Payable on or Before September 16, 2023

Full year 2023 earnings released: EPS: ₹136 (vs ₹134 in FY 2022)

Pfizer Limited to Report Fiscal Year 2023 Results on May 15, 2023

Here's Why Pfizer (NSE:PFIZER) Can Manage Its Debt Responsibly

Third quarter 2023 earnings released: EPS: ₹32.93 (vs ₹31.46 in 3Q 2022)

Pfizer India Appoints Meenakshi Nevatia as CEO

Second quarter 2023 earnings released: EPS: ₹67.99 (vs ₹31.25 in 2Q 2022)

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹67.99 (vs ₹31.25 in 2Q 2022)

Upcoming dividend of ₹30.00 per share

Pfizer Limited Announces Interim (Special) Dividend for the Financial Year Ending March 31, 2023, Payable on or Before September 30, 2022

Pfizer Limited Approves Declaration of Dividend for the Financial Year Ended March 31, 2022

Upcoming dividend of ₹35.00 per share

Pfizer Announces Resignation of S. Sridhar as Managing Director

Pfizer Limited Proposes Dividend for the Financial Year Ended March 31, 2022

First quarter 2023 earnings released

Pfizer Limited Proposes Dividend for the Financial Year Ended March 31, 2022

Mylan Pharmaceuticals Private Limited completed the acquisition of off-patent branded and generic established medicines business from Pfizer Limited (BSE:500680).

Pfizer Limited to Report Q1, 2023 Results on Aug 05, 2022

A Look At The Intrinsic Value Of Pfizer Limited (NSE:PFIZER)

Now 20% undervalued after recent price drop

Price target decreased to ₹5,201

Now 21% undervalued after recent price drop

Full year 2022 earnings released: EPS: ₹134 (vs ₹109 in FY 2021)

Pfizer Limited Recommends Dividend for the Financial Year Ended March 31, 2022, Payable on or before September 23, 2022

Price target decreased to ₹5,654

Insufficient new directors

Insufficient new directors

Pfizer (NSE:PFIZER) Could Easily Take On More Debt

Pfizer and FDA Dropped Data Bombshell on Covid Vaccine Consumers

Price target decreased to ₹5,749

Calculating The Fair Value Of Pfizer Limited (NSE:PFIZER)

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Pfizer Limited Announces Board Changes

Pfizer Limited Announces Resignation of R. A. Shah as an Independent Director